Guttman-Yassky, Emma, Stephan Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, and Diamant Thaci. “Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s271. Accessed July 22, 2024. https://jofskin.org/index.php/skin/article/view/2382.